Eledon Pharmaceuticals
ELDN
44 hedge funds and large institutions have $4.26M invested in Eledon Pharmaceuticals in 2016 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 12 increasing their positions, 10 reducing their positions, and 12 closing their positions.
20% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 10
8% less funds holding
Funds holding: 48 → 44 (-4)
11.49% less ownership
Funds ownership: 23.81% → 12.32% (-11%)
33% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 12
86% less capital invested
Capital invested by funds: $29.7M → $4.26M (-$25.4M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$797K |
| 2 |
Renaissance Technologies
New York
|
+$457K |
| 3 |
EA
Emerald Acquisition
Seattle,
Washington
|
+$221K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$163K |
| 5 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$124K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
-$3.64M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$2.94M |
| 3 |
SAM
Senzar Asset Management
New York
|
-$2.82M |
| 4 |
Franklin Resources
San Mateo,
California
|
-$2.62M |
| 5 |
Alyeska Investment Group
Chicago,
Illinois
|
-$1.78M |
ELDN Hedge Fund Activity: Q3 2016 in Review
44 of the 3,759 institutional investors tracked by Wall St. Rank reported a position in Eledon Pharmaceuticals (ELDN) for Q3 2016, worth a combined $4.26M — down 86% from $29.7M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of ELDN and 8 opened new positions — a net loss of 4 holders — while 10 trimmed existing stakes and 12 added.
The largest buyer was Bridgeway Capital Management, adding an estimated $797K. The largest seller was Perceptive Advisors, exiting entirely with an estimated $3.64M sold.
- 44 institutional investors held Eledon Pharmaceuticals (ELDN) as of Q3 2016, down from 48 in Q2 2016.
- Funds reported $4.26M of Eledon Pharmaceuticals stock for Q3 2016, down 86% quarter-over-quarter.
- 8 funds opened new Eledon Pharmaceuticals positions in Q3 2016 and 12 closed out, a net change of -4 holders.
- The largest Eledon Pharmaceuticals buyer in Q3 2016 was Bridgeway Capital Management, an estimated $797K added.
- The largest Eledon Pharmaceuticals seller in Q3 2016 was Perceptive Advisors, an estimated $3.64M sold.
Based on aggregated 13F filings for Q3 2016.